IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia
Biomark Res. 2025 Apr 14;13(1):61. doi: 10.1186/s40364-025-00769-z. ABSTRACT BACKGROUND: Surface antigens of potential clinical significance remain under-characterized in AML. The European Leukemia Network classifies normal …